Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.
Enorama Pharma AB (ERMA) - Total Assets
Latest total assets as of September 2025: Skr12.57 Million SEK
Based on the latest financial reports, Enorama Pharma AB (ERMA) holds total assets worth Skr12.57 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Enorama Pharma AB - Total Assets Trend (2014–2024)
This chart illustrates how Enorama Pharma AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Enorama Pharma AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Enorama Pharma AB's total assets of Skr12.57 Million consist of 95.4% current assets and 4.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 13.1% |
| Accounts Receivable | Skr1.41 Million | 8.9% |
| Inventory | Skr11.28 Million | 70.9% |
| Property, Plant & Equipment | Skr142.00K | 0.9% |
| Intangible Assets | Skr592.00K | 3.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Enorama Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enorama Pharma AB's current assets represent 95.4% of total assets in 2024, an increase from 0.7% in 2014.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, up from 0.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 70.9% of total assets.
Enorama Pharma AB Competitors by Total Assets
Key competitors of Enorama Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Enorama Pharma AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Enorama Pharma AB generates 0.99x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Enorama Pharma AB is currently not profitable relative to its asset base.
Enorama Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.71 | 2.90 | 0.69 |
| Quick Ratio | 0.52 | 1.76 | 0.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-5.00 Million | Skr 14.90 Million | Skr -5.79 Million |
Enorama Pharma AB - Advanced Valuation Insights
This section examines the relationship between Enorama Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.00 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -53.8% |
| Total Assets | Skr15.89 Million |
| Market Capitalization | $549.55K USD |
Valuation Analysis
Below Book Valuation: The market values Enorama Pharma AB's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Enorama Pharma AB's assets decreased by 53.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enorama Pharma AB (2014–2024)
The table below shows the annual total assets of Enorama Pharma AB from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr15.89 Million | -53.78% |
| 2023-12-31 | Skr34.38 Million | -29.42% |
| 2022-12-31 | Skr48.72 Million | -4.34% |
| 2021-12-31 | Skr50.93 Million | +24.52% |
| 2020-12-31 | Skr40.91 Million | -3.94% |
| 2019-12-31 | Skr42.58 Million | +9.67% |
| 2018-12-31 | Skr38.83 Million | +150.72% |
| 2017-12-31 | Skr15.49 Million | +13.66% |
| 2016-12-31 | Skr13.63 Million | +48.63% |
| 2015-12-31 | Skr9.17 Million | +148.19% |
| 2014-12-31 | Skr3.69 Million | -- |